SCHEMBL2368646

SCHEMBL2368646

c1ncc2c(-c3ccc4c(c3)OCO4)csc2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 10/20 0.51
CYP2D6 P10635 10/20 0.51
CLK4 Q9HAZ1 9/20 0.51
CYP2C19 P33261 9/20 0.51
CYP3A4 P08684 9/20 0.51
TSHR P16473 8/20 0.51
HSD17B10 Q99714 9/20 0.51
CYP2C9 P11712 7/20 0.51
MAPK1 P28482 6/20 0.51
ALDH1A1 P00352 5/20 0.51
ALOX15 P16050 4/20 0.51
HPGD P15428 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
USP2 O75604 3/20 0.48
HTT P42858 2/20 0.48
PAX8 Q06710 1/20 0.48
PIP4K2C Q8TBX8 1/20 0.48
LMNA P02545 6/20 0.48
CLK1 P49759 5/20 0.46
DYRK1A Q13627 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459354 0.78 MAPT (0.48) CYP1A2CYP2D6CLK4CYP2C19CYP3A4
SCHEMBL5803878 0.76 HTT (0.47) CYP1A2CYP2D6CLK4CYP2C19CYP3A4
SCHEMBL2367997 0.74 LMNA (0.49) CLK4ALDH1A1USP2LMNADYRK1A
SCHEMBL30700550 0.74 DHFR (0.41) CLK4ALDH1A1HTTLMNACLK1
SCHEMBL2368915 0.74 SMN1; SMN2 (0.38) CYP1A2CYP2C19CYP3A4TSHRHSD17B10
SCHEMBL2368808 0.72 LMNA (0.55) MAPK1ALDH1A1HTTPAX8PIP4K2C
SCHEMBL2368684 0.72 HTT (0.58) ALDH1A1HTTPIP4K2CLMNAMAPT
SCHEMBL14964882 0.71 FGFR1 (0.53) CYP1A2CLK4CYP2C19CYP2C9MAPK1
SCHEMBL7614422 0.70 CLK4 (0.49) CYP1A2CYP2D6CLK4CYP2C19CYP3A4
SCHEMBL2368945 0.69 MAPT (0.53) CYP1A2CYP2D6CYP2C19CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022076-B2 Thieno[2,3-d]pyrimidine derivatives as potassium channel modulators; antiarrhythmia agents XENTION LIMITED (GB) 2011-09-20 US disclosed
US-20050026935-A1 Compounds XENTION DISCOVERY LTD. 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026935-A1 Compounds KCNJ11, KCNJ1, KCNH1 CYP1A2 226/4885CYP2D6 225/4885CLK4 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.